These data further demonstrate the potential of a highly selective ROCK2 inhibitor to reverse established liver fibrosis via combined targeting of fibrotic, inflammatory, and metabolic signaling pathways in vivo. This evidence concerns the gene ROCK2 and Hepatic fibrosis.